Cbl-b-IN-29
Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research[1].
Product Specifications
CAS Number
[3070411-10-5]
UNSPSC
12352005
Target
E1/E2/E3 Enzyme; Interleukin Related
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease
Field of Research
Cancer; Inflammation/Immunology
Smiles
CN1C([C@]2(C[C@@H](C)C2)C3=CC(C4=CC5=C(C([C@@H](C)NC6CCCC6)=CC=C5F)NC4=O)=CC=C3)=NN=C1
Molecular Formula
C30H34FN5O
Molecular Weight
499.62
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
